Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig P Carden

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
CA: a Cancer Journal for Clinicians|January 6, 2011
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicTimothy A Yap, Shahneen K Sandhu, Craig P Carden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2010
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapyAndre T Brunetto, Craig P Carden, James Myerson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 2, 2008
Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reportsCraig P Carden, James S Myerson, Sanjay Popat, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Molecular Cancer Therapeutics|January 11, 2011
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2Siân Rizzo, Jenny M Hersey, Paul Mellor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2014
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumorsRobin L Jones, Edward S Kim, Pilar Nava-Parada, et al.
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
Cancer Research|April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancerGerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
CA: a Cancer Journal for Clinicians|January 6, 2011
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicTimothy A Yap, Shahneen K Sandhu, Craig P Carden, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 21, 2010
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapyAndre T Brunetto, Craig P Carden, James Myerson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 2, 2008
Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reportsCraig P Carden, James S Myerson, Sanjay Popat, et al.
Drug Discovery Today|December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Molecular Cancer Therapeutics|January 11, 2011
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2Siân Rizzo, Jenny M Hersey, Paul Mellor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2014
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumorsRobin L Jones, Edward S Kim, Pilar Nava-Parada, et al.
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
Cancer Research|April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancerGerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
Pageof 2